A Phase 4 interventional study of Aliskiren and Aliskiren in Microalbuminuria, Macroalbuminuric Diabetic Nephropathy and Diabetes, sponsored by Cook County Health. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-10-28.
Sponsored by Cook County Health · Phase 4, Interventional, and Treatment
Study Hypothesis:
Reduction in albuminuria has been shown to decrease progression of diabetic
nephropathy. In diabetic nephropathy patients treated with maximal
antihypertensive doses with dual RAAS blockade (total daily dose valsartan 320
mg and either enalapril 40 mg or benazepril 40 mg daily, or losartan 100mg), persistent
albuminuria reflects further additional RAAS activation. Microvascular renal
disease due to increased RAAS activation may be more effectively treated with
triple blockade by the addition of a direct renin inhibitor (DRI) Aliskiren.
534 studies on the registry are indexed under Diabetic Nephropathies; 107 are open to participants now.
This study's enrollment of 2 is below the median of 80 across 377 interventional studies indexed under Diabetic Nephropathies.
Browse Diabetic Nephropathies studies →Cook County Health is the lead sponsor of 28 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Aliskiren 150 mg daily for 2 weeks and then increased to 300 mg daily for 4 weeks.
Drug: Aliskiren
Aliskiren 150 mg daily for 2 weeks and then increased to 300mg daily for 4 weeks
Drug: Aliskiren
Aliskiren 150mg daily for 2 weeks and increased to 300 mg daily for 4 weeks.
Also known as: Tekturna
Aliskiren 150mg daily for 2 weeks and increased to 300 mg daily for 4 weeks.
Also known as: Tekturna
Reduction in albuminuria/proteinuria
Time frame: 6 weeks
Safety of Triple RAAS inhibition with ACE-I, ARB and DRI
Time frame: 6 weeks
This study is terminated, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cook County Health